Clinical Trials Browser

Phase 2/3 × OTHER × Cholangiocarcinoma × Clear all

NCT04669496 2025-09-04

Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Phase 2/3 Active not recruiting

Gastrointestinal

Cholangiocarcinoma

NCT06355427 2025-04-11

FAPIChol

Phase 2/3 Recruiting

Gastrointestinal

Cholangiocarcinoma

NCT06923475 2025-04-11

NEODISCO

Phase 2/3 Not yet recruiting

Gastrointestinal

Cholangiocarcinoma, Klatskin Tumor

NCT06037980 2025-02-17

PURITY

Phase 2/3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT02108145 2019-08-01

Percutaneous Bilateral Versus Unilateral Metal Stent for Hilar Cholangiocarcinoma

Phase 2/3 Unknown

Gastrointestinal

Jaundice, Cholangiocarcinoma, Klatskin Tumor

NCT02482454 2017-08-01

Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma

Phase 2/3 Active not recruiting

Gastrointestinal

Cholangiocarcinoma

NCT01755013 2017-02-20

Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma

Phase 2/3 Unknown

Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

NCT01739465 2013-02-26

Comparison of Endoscopic Radiofrequency Ablation Versus Photodynamic Therapy for Inoperable Cholangiocarcinoma

Phase 2/3 Unknown

Gastrointestinal

Adenocarcinoma, Bile Duct Diseases, Biliary Tract Diseases, Carcinoma, Constriction, Pathologic, Digestive System Diseases, Neoplasms, Neoplasms by Site, Cholangiocarcinoma